STATUS * ACCESS & THE RECORD
BPC-157 Legal Status, FDA 503A Category, and Compounding Access
Access is under active FDA review and may expand in 2026 — but the current status is unchanged. Here is exactly what the FDA record says, and what it does not.
The momentum first: BPC-157 is under active FDA review for 2026
BPC-157 legal status is moving. BPC-157 — listed by the FDA as 'BPC-157 (free base)' and 'BPC-157 acetate' — is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23–24, 2026, as a bulk drug substance 'being considered for inclusion on the 503A Bulks List' [9]. The same agenda also lists KPV, TB-500, and MOTs-C [9]. That is real forward motion: the substance is on the calendar for evaluation, not sitting untouched.
Read that precisely, because the precision is the point. A PCAC agenda is a scheduled evaluation and discussion. It is not a listing decision, not a reclassification, and not a change in BPC-157's current status [9]. A PCAC discussion is advisory; inclusion on a final 503A bulks list is decided by FDA rulemaking informed by that committee, and 'being discussed by PCAC' is a step in evaluation, not the outcome [10]. So the accurate headline is: access is under active review and may expand in 2026 — and as of today nothing has changed.
The current fact: BPC-157 is in FDA 503A Category 2
Here is the status as it stands. The FDA identified BPC-157 as a bulk drug substance that may present significant safety risks and placed it in 'Category 2' for 503A compounding, effective with the FDA's September 29, 2023 update to the list of nominated substances [11]. The agency cited concerns including potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization [11].
What Category 2 means is specific. Under the FDA's interim policy, Category 2 covers substances that were nominated with enough information to evaluate but that the FDA identified as raising significant safety risks — and, crucially, Category 2 substances are not covered by the enforcement-discretion policy that applies to Category 1 [10]. So as a Category 2 substance, BPC-157 is not within the FDA's enforcement-discretion policy for 503A compounding, and it is not an FDA-approved drug [11]. Approval of a finished drug is a separate question from whether a bulk substance may be used in compounding, and BPC-157 is neither approved nor on a final bulks list [10].
What we are not claiming
Because BPC-157 attracts a lot of confident internet rumor, here is the discipline this page holds. No reclassification has been stated as done, dated, or certain — the current category is Category 2, which is the last FDA action confirmable from FDA.gov [11]. The July 2026 PCAC meeting is referenced only as a scheduled discussion of a substance under evaluation, never as a decision or an assumed outcome [9].
There are circulating claims — that roughly 14 of the peptides placed in Category 2 in 2023 were 'moved back' toward Category 1 in early 2026, and that BPC-157 was 'removed' from Category 2 around April 2026 — that could not be confirmed from any authoritative FDA source, and the most candid versions admit the formal reclassification is 'still pending' [10]. This page does not present any of that as fact. Notably, the FDA's own PCAC agenda still lists BPC-157 as 'being considered for inclusion' for July 2026, which is consistent with its evaluation being ongoing rather than resolved [9].
How lawful compounded peptide access works
Compounded medication access in the U.S. follows one lawful pathway, and it is worth stating in general terms. A patient is first evaluated by an appropriately licensed prescriber — in person or through a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate [12]. If it is appropriate and lawful, the prescriber issues a valid, patient-specific prescription. That prescription is then dispensed by a state-licensed 503A compounding pharmacy (patient-specific) or, for office and batch use, sourced from an FDA-registered 503B outsourcing facility [12].
There is a hard ingredient gate in that chain. A compounder may use a requested active ingredient only if it is eligible under the 503A/503B bulk-substance rules — meaning it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the applicable FDA bulks list [10]. An ingredient the FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands [12]. For BPC-157, that is the operative caveat: as a Category 2 substance, it is not eligible for routine 503A compounding under the current status [11]. Telehealth is one channel for the prescriber-evaluation step — it is a route to a licensed-prescriber consultation, not a separate legal status, and it does not expand which substances may be compounded [12].
Access and regulatory questions
Is BPC-157 legal?
BPC-157 is not an FDA-approved drug and is not on a final 503A bulks list; the FDA placed it in 503A 'Category 2' (substances identified as possibly presenting significant safety risks), effective with its September 29, 2023 update [11]. As a Category 2 substance it is outside the FDA's enforcement-discretion policy for 503A compounding [10]. This is general regulatory information, not legal advice.
Can you get BPC-157 from a compounding pharmacy?
Under current FDA status, BPC-157 is not eligible for routine 503A compounding, because the agency placed it in Category 2 and Category 2 substances are not within the enforcement-discretion policy that applies to Category 1 [11][10]. Lawful compounding generally requires a licensed-prescriber evaluation, a valid prescription, and an ingredient that is eligible under the 503A/503B rules — which BPC-157 currently is not [12].
What is the FDA 503A status of BPC-157?
BPC-157 ('BPC-157 (free base)' and 'BPC-157 acetate') is in 503A Category 2, effective with the FDA's September 29, 2023 nominated-substances update, citing concerns including potential immunogenicity for certain routes and peptide impurity and characterization complexities [11]. It is also individually listed on the July 23–24, 2026 PCAC agenda as a substance being considered for the 503A bulks list — a scheduled discussion, not a decision [9].